超重/肥胖与耐多药结核病之间的关联。
Association between overweight/obesity and multidrug-resistant tuberculosis.
机构信息
1 Socios en Salud Sucursal Perú, Lima, Perú.
Escuela de Medicina, Facultad de Ciencias de la Salud, Universidad Peruana de Ciencias Aplicadas, Lima, Perú.
出版信息
Rev Peru Med Exp Salud Publica. 2023 Jan-Mar;40(1):59-66. doi: 10.17843/rpmesp.2023.401.12138. Epub 2023 Jun 23.
OBJECTIVE.: To evaluate the association between overweight/obesity and multidrug resistance in patients with and without a history of tuberculosis treatment.
MATERIALS AND METHODS.: Cross-sectional study of secondary data from a tuberculosis cohort, which included anthropometric and drug-sensitivity testing data at the baseline visit of patients with and without previous tuberculosis treatment.
RESULTS.: We evaluated 3,734 new cases and 766 with a history of having received treatment for tuberculosis. Overweight/obesity was not associated with multidrug resistance in patients with a history of tuberculosis treatment, with a prevalence ratio of 0.97 and a 95% confidence interval of 0.68-1.38.
CONCLUSIONS.: Overweight/obesity is not associated with multidrug resistance in tuberculosis. Overweight/obesity is a dynamic process that may influence the relationship between the immune system and the metabolic system.
目的
评估有和无结核病治疗史的患者中超重/肥胖与耐多药之间的关联。
材料和方法
这是一项结核病队列的二次数据的横断面研究，其中包括基线就诊时有和无既往结核病治疗的患者的人体测量和药物敏感性检测数据。
结果
我们评估了 3734 例新发病例和 766 例有结核病治疗史的病例。超重/肥胖与有结核病治疗史的患者的耐多药无关，其患病率比为 0.97，95%置信区间为 0.68-1.38。
结论
超重/肥胖与结核病的耐多药无关。超重/肥胖是一个动态的过程，可能会影响免疫系统和代谢系统之间的关系。
Zotero 插件